Standout Papers
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023)
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I (2021)
Immediate Impact
5 from Science/Nature 72 standout
Citing Papers
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout
Works of Conleth G. Murphy being referenced
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
2021 Standout
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Conleth G. Murphy | 978 | 417 | 262 | 308 | 54 | 1.4k | |
| Véronique D’Hondt | 763 | 329 | 265 | 287 | 81 | 1.3k | |
| Henrik Roed | 738 | 508 | 328 | 305 | 53 | 1.7k | |
| Guidalberto Fabris | 571 | 319 | 166 | 225 | 46 | 1.2k | |
| Coraline Dubot | 821 | 349 | 255 | 222 | 59 | 1.3k | |
| Daniel Vorobiof | 915 | 383 | 85 | 148 | 60 | 1.5k | |
| G. Viale | 845 | 339 | 105 | 496 | 45 | 1.5k | |
| Andrea Michelotti | 727 | 235 | 338 | 177 | 59 | 1.2k | |
| Antonio Febbraro | 636 | 310 | 168 | 245 | 56 | 1.2k | |
| Jorge Chaves | 886 | 354 | 203 | 203 | 41 | 1.1k | |
| Maja J.A. de Jonge | 826 | 416 | 123 | 852 | 40 | 1.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...